Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
26.54
+0.37 (1.41%)
Nov 21, 2024, 4:00 PM EST - Market closed
Company Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia.
Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Immunovant, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 207 |
| CEO | Peter Salzmann |
Contact Details
Address: 320 West 37th Street, 6th Floor New York, New York 10018 United States | |
| Phone | (917) 580-3099 |
| Website | immunovant.com |
Stock Details
| Ticker Symbol | IMVT |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001764013 |
| CUSIP Number | 45258J102 |
| ISIN Number | US45258J1025 |
| Employer ID | 83-2771572 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter Salzmann M.B.A., M.D. | Chief Executive Officer and Director |
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board |
| Dr. Jay S. Stout Ph.D. | Chief Technology Officer |
| Eva Renee Barnett M.B.A. | Chief Financial Officer |
| Lauren Schrier M.B.A. | Vice President of Marketing |
| Christine Blodgett | Senior Vice President of Human Resources |
| Dr. William L. Macias M.D., Ph.D. | Chief Medical Officer |
| Andy Deig | Senior Vice President of Strategic Finance |
| Dr. Michael Geffner M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Julie Kirschling | Senior Vice President of Program and Alliance Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Sep 9, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 8-K | Current Report |
| Aug 6, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |
| Jun 28, 2024 | ARS | Filing |
| Jun 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 26, 2024 | DEF 14A | Other definitive proxy statements |